[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Table 6

Multivariate logistic regression analysis of the safety of pyrrotinib for the treatment of HER2-positive breast cancer.

Variables	OR	95% CI
Age (>50 years old vs. ≤50 years old)	1.263	1.059~1.738	0.042
ECOG score (2 points vs. ≤1 point)	1.185	1.032~1.835	0.035
Comorbidities (yes vs. no)	1.180	0.927~1.625	0.094
Chemotherapy drugs (capecitabine vs. others)	0.893	0.627~0.964	0.014